PF-573228

Catalog No.S2013

PF-573228 Chemical Structure

Molecular Weight(MW): 491.49

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 147 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • FAK inhibition blunted the increased migration induced by PGC1α depletion. G361 cells were subjected to 24 h transwell migration assays in the presence of DMSO or various doses of FAK inhibitor PF-573228. Images represent three pictures captured with scale bar representing 100 μm.

    Nature, 2016, 537(7620):422-429.. PF-573228 purchased from Selleck.

    (b) Using PF-573228 at a concentration range of 0.01–10 μM for 24 hours decreased phosphorylated FAK expression in a time-dependent manner, and there was a 70% inhibition rate at the range of 5–10 μM.

    Sci Rep, 2017, 7:43146. PF-573228 purchased from Selleck.

  • a. Gelatin degradation by NCI-H460/R and COR-L23 cells treated with DOX, PF-573228, WZ811 and their combinations for 24 h. Images were captured using a 20× objective on a fluorescence microscope and representative examples are presented on the left part of the panel. At least 100 cells were analyzed per experiment. All experiments were performed at least three times. Merged channels show fluorescent gelatin (green), actin (red) and nuclei (blue) staining; dark areas represent spots of degraded gelatin. Scale bar = 100 μm. Corresponding histograms for each cell line are presented in the right part of the panel showing percentages of degraded gelatin areas relative to the cell volume. Each bar represents mean value ± S.E. * indicates p < 0.05 compared to untreated control cells; # indicates p < 0.05 compared to cells treated with PF-573228; $ indicates p < 0.05 compared to cells treated with WZ811.

    Cell Oncol (Dordr), 2017, 40(1):47-62.. PF-573228 purchased from Selleck.

    OVISE cells were incubated for 25 hr at the indicated concentrations of the FAK inhibitors. Immunoblots were performed to assess inhibition of auto-phosphorylation by the FAK inhibitors.

    PLoS One 2014 9(2), e88588. PF-573228 purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by Focal adhesion kinase (FAK) inhibitor PF-573228. PF-573228 was applied on NCI-H460 and COR-L23, both derived from large cell lung carcinoma. Hence, it acted similarly showing strong inhibitory potential in both cell lines by suppressing the growth of 50% of cells between 4 and 7 礛.

    2014 Dr.Milica Pesic from Institute for Biological Research. PF-573228 purchased from Selleck.

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.
Targets
FAK [1]
(Cell-free assay)
4 nM
In vitro

PF 573228 blocks the phosphorylation of FAK Tyr397 in REF52 cells, PC3 cells, SKOV-3 cells, L3.6p1 and F-G, MDCK cells with IC50 of 30-500 nM. However, PF 573228 (1 μM) with 80% inhibition of FAK phosphorylation fails to inhibit cell growth or apoptosis. Similar treatment of cells with PF-228 resulted in inhibition of serum or FN-directed migration and decreased focal adhesion turnover. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A431 M1PyUGtqdmG|ZTDhd5NigQ>? NFXFNot,OTBizszN NEnENpdFVVOR M2\mTYlvcGmkaYTzJGZCUyCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGxJI5O M1[1Z|E4Ozl3NUm0
REF52 NWfISmgzU2mwYYPlJIF{e2G7 MVP+NVAh|ryP NXO3SZl2TE2VTx?= MXnpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE[DSzDUfZI{QTdid3n0bEBKSzVyIH;mJJ4yODBibl2= MWKxO|M6PTV7NB?=
PC3 M3:5bWtqdmG|ZTDhd5NigQ>? NVv1SHJnhjFyIN88US=> M1HGfWROW09? NFrJdWxqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIF\BT{BVgXJ|OUege4l1cCCLQ{WwJI9nKDFyMDDuUS=> Moi0NVc{QTV3OUS=
SKOV-3 M1jpU2tqdmG|ZTDhd5NigQ>? NX3VTY1NhjFyIN88US=> NIH0cGVFVVOR Ml\EbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCIQVugWJlzOzl5IIfpeIghUUN3MDDv[kA2OCCwTR?= Ml76NVc{QTV3OUS=
L3.6p1 MoTFT4lv[XOnIHHzd4F6 MUj+NVAh|ryP NHv3V2ZFVVOR MUnpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE[DSzDUfZI{QTdid3n0bEBKSzVyIH;mJFMxOCCwTR?= NIe5SncyPzN7NUW5OC=>
F-G NGLVfZlMcW6jc3WgZZN{[Xl? MljiglExKM7:TR?= MXnEUXNQ MV\pcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE[DSzDUfZI{QTdid3n0bEBKSzVyIH;mJFMxKG6P MV6xO|M6PTV7NB?=
MDCK MWPLbY5ie2ViYYPzZZk> NFnaVVh,OTBizszN NE[1[5VFVVOR NYmxbplJcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDGRWshXHm{M{m3JJdqfGhiSVO1NEBw\iB3MECgcm0> M2P6WFE4Ozl3NUm0
PC3 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH3jVpMyOCEQvF2= Mo\2SG1UVw>? NYHoZ2s2e2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bE4> MWqxO|M6PTV7NB?=
REF52 MnXUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF;aOnIyOCEQvF2= NI\KeXhFVVOR MmXKd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aD6= M2TEeVE4Ozl3NUm0
MDCK M1K3UWFxd3C2b4Ppd{Bie3OjeR?= MX6xNEDPxE1? M3vtOmROW09? MnTxbY5lfWOnczDhdI9xfG:|aYO= Mm\UNVc{QTV3OUS=
REF52 NVe1NmNRSXCxcITvd4l{KGG|c3H5 NHvNeFAyOCEQvF2= M3zaVmROW09? NI\ZfG5qdmS3Y3XzJIFxd3C2b4Ppdy=> MVixO|M6PTV7NB?=
REF52 NXW1dVgxTnWwY4Tpc44h[XO|YYm= M3P4b|ExKM7:TR?= MWjEUXNQ NV\0Vppj[myxY3vzJJNmenWvIHHu[EBHVi2|dHnteYxifGWmIH3p[5JifGmxbh?= MXqxO|M6PTV7NB?=
platelet MUjGeY5kfGmxbjDhd5NigQ>? M4X0XFEh|ryP MnnxSG1UVw>? NYfNT2NycW6qaXLpeJMheGyjdHXs[ZQh[WepcnXnZZRqd25iYX7kJJNxemWjZHnu[y=> NIPaPHcyQTdzNkiwNy=>
platelet M4WzdGZ2dmO2aX;uJIF{e2G7 NEfR[HcyKM7:TR?= NG\obmJFVVOR MXjs[YFleyC2bzDpcohq[mm2aX;uJI9nKFCDSzDhcoQhSUuW NFjlT4QyQTdzNkiwNy=>
platelet M{HJSWZ2dmO2aX;uJIF{e2G7 Ml\lNUDPxE1? Ml3DSG1UVw>? M3TrN4Jtd2OtczDjZYxkcXWvIH3vZoltcXqjdHnvckBidmRiZHXud4Uh\3KjboXs[UB{\WO{ZYTpc44> MkLpNVk4OTZ6MEO=
4T1 NHPiPWlHfW6ldHnvckBie3OjeR?= MUTEUXNQ MmLFZYJwdGm|aHXzJJRp\SCrboTldoFkfGmxbjDi[ZR4\WWwIN8yN{BqdnSnZ4LpckBidmRiVN8yVk1KUQ>? M1LYR|E6PzRyNEOz
MCF7 Mnf5T4lv[XOnIHHzd4F6 NHXvdm5,OTBizszN NEHiSm1FVVOR NHXtVJFqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIF\BT{BVgXJ|OUege4l1cCCLQ{WwJI9nKDR|MDDuUS=> M1\BXVIxOzV2N{iw
TamR MWnLbY5ie2ViYYPzZZk> MkfIglExKM7:TR?= M4L3[2ROW09? M3TkdIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRlHLJHR6ejN7NzD3bZRpKEmFNUCgc4YhPTBibl2= NXHq[mg3OjB|NUS3PFA>
FasR NYnlRXViU2mwYYPlJIF{e2G7 NIrOfnR,OTBizszN NVfObFhpTE2VTx?= MofUbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCIQVugWJlzOzl5IIfpeIghUUN3MDDv[kAyOzBibl2= Mnj5NlA{PTR5OEC=
TamR MUTGeY5kfGmxbjDhd5NigQ>? NFnHOFAyKM7:TR?= MUXEUXNQ NVjjVJhFcW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MnrPNlA{PTR5OEC=
FasR NH7UVINHfW6ldHnvckBie3OjeR?= MUmxJO69VQ>? M1G0NGROW09? NVjGPWdkcW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NE[3TXIzODN3NEe4NC=>
endothelial cell NXjF[3pQU2mwYYPlJIF{e2G7 MX60NEBvVQ>? MkXvSG1UVw>? NV3o[JpOcW6qaXLpeJMhUDKRMj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDGRWs> MXiyNVIyOjRyMh?=
endothelial cell MWrGeY5kfGmxbjDhd5NigQ>? MXe0NEBvVQ>? MmTuSG1UVw>? MULpcohq[mm2czDINm8zNWmwZIXj[YQhe3S{ZYPzJIZq[mW{IH\vdo1ifGmxbh?= M4LrcVIyOjF{NECy
endothelial cell NWjoPIV4SXCxcITvd4l{KGG|c3H5 M4S1[VQxKG6P M3fTOWROW09? NEK2S3pqdmirYnn0d{BieG:ydH;zbZM> MYiyNVIyOjRyMh?=
GH3 MnLzSpVv[3Srb36gZZN{[Xl? M17Yc|Mh|ryP MVzEUXNQ NFn5T5NqdmO{ZXHz[ZMhUUtqQ3GpJIFueGyrdIXk[S=> Ml7JNlE6OjV3MUK=
GH3 MWDGeY5kfGmxbjDhd5NigQ>? NX3qUnB4OyEQvF2= M1PlUGROW09? NUXObJlN\W6qYX7j[ZMhSkuFYT3jbIFvdmWuIHHjeIl3cXS7 MXyyNVkzPTVzMh?=
HUVEC MXHjfZRwfG:6aXPpeJkh[XO|YYm= NFXLdHl,OTBizszN MUjEUXNQ MlnpbY1x[Wm{czDlcoRwfGinbHnhcEBk\WyuII\pZYJqdGm2eR?= M1\YdlIzODd3MEW3
HUVEC Mme2T4lv[XOnIHHzd4F6 MXe1JO69VQ>? NUjLcnh7TE2VTx?= M{fwOolvcGmkaYTzJGZCUyCtaX7hd4Uh[WO2aY\peJk> MXiyNlA4PTB3Nx?=
HUVEC NWDmPYs{TnWwY4Tpc44h[XO|YYm= M1fmU|Uh|ryP NGTqdW5FVVOR NE[zSWVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NWThfphbOjJyN{WwOVc>
HUVEC MW\BdI9xfG:|aYOgZZN{[Xl? M1fYSlUh|ryP MX;EUXNQ MWTpcoR2[2W|IHHwc5B1d3Orcx?= M{\PSVIzODd3MEW3
HUVEC MXHGeY5kfGmxbjDhd5NigQ>? MmHrOUDPxE1? NI\mW|RFVVOR MX7pcZBm\GW|IHXu[I91cGWuaXHsJINmdGxibXnndoF1cW:wIHHu[EBidHSncoOgeIhmKGOnbHz1cIFzKGGldHnuJIN6fG:|a3Xs[ZRwdg>? MnvoNlIxPzVyNUe=
HUVEC NXWzNXdDTnWwY4Tpc44h[XO|YYm= MnztOUDPxE1? Mkm4SG1UVw>? NVHK[4Vs[myxY3vzJGhWXkWFIIPwdo92fGmwZzDvckBkd2yuYXflckBKKGenbIO= MoDnNlIxPzVyNUe=
human peripheral blood T cells MXzLbY5ie2ViYYPzZZk> M4HQUJ4yOCEQvF2= MlrPSG1UVw>? MVPpcohq[mm2czDzbZRmNXOyZXPp[olkKHCqb4PwbI9zgWyjdHnvckBw\iCIQVu= Mn\mNlM6OjhzOEi=
human peripheral blood T cells NITDUY9HfW6ldHnvckBie3OjeR?= NF74OJJ,OTBizszN M2XoeWROW09? NUfJeIpZcW2yYXnyd{BVS1JvaX7keYNm\CCWIHPlcIwhdW:{cHjvcI9ocWOjbDDjbIFv\2W|IHHu[EBidHSncoOgZYN1cX[rdImgc4YhWmixQR?= NVv6dIM3OjN7MkixPFg>
human peripheral blood T cells M2\kN2Z2dmO2aX;uJIF{e2G7 MX\+NVAh|ryP MU\EUXNQ MYnpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gXmFRNTdyIHHu[EBNSVR? NVXYfXk{OjN7MkixPFg>
human peripheral blood T cells M3jWU2Z2dmO2aX;uJIF{e2G7 MmWyglExKM7:TR?= M4TWTmROW09? NH;2b4ZqdXCjaYLzJGFvfGmpZX6t[IVx\W6mZX70JHQh[2WubDDjc45rfWejdHnvci=> NGfkVFczOzl{OEG4PC=>

... Click to View More Cell Line Experimental Data

In vivo Inhibition of FAK by PF-573,228 in Ctrl-MT mice leads to a significant suppression of mammary tumorigenesis as well as lung metastasis. In contrast, treatment of MFCKO-MT mice with PF-573,228 did not affect the initiation of mammary tumors in these mice, as would be expected due to the absence of FAK in mammary epithelial cells of these mice [2].

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Purified activated FAK kinase domain (amino acids 410–689) is reacted with 50 μM ATP, and 10 μg/well of a random peptide polymer of Glu and Tyr (molar ratio of 4:1), poly(Glu/Tyr) in kinase buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 48 mM MgCl2) for 15 min. Phosphorylation of poly(Glu/Tyr) is challenged with serially diluted compounds at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is run in triplicate. Phosphorylation of poly(Glu/Tyr) is detected with a general anti-phospho-tyrosine (PY20) antibody, followed by horseradish peroxidase-conjugated goat anti-mouse IgG antibody. The standard horseradish peroxidase substrate 3, 3
Cell Research:

[1]

+ Expand
  • Cell lines: REF52 or PC3 cells
  • Concentrations: ~10 μM
  • Incubation Time: 3 days
  • Method:

    Growth assays are performed by seeding 1 × 104 REF52 or PC3 cells/well of a 24-well plate in triplicate 24 h prior to daily treatment with the indicated concentrations of each inhibitor for 3 days. Subsequently, the cells are harvested and counted.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Ctrl-MT and MFCKO-MT mice
  • Formulation: --
  • Dosages: 5 mg/kg
  • Administration: oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 26 mg/mL (52.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+2% Tween 80+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 491.49
Formula

C22H20F3N5O3S

CAS No. 869288-64-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Would you please let me know the detail of how to dissolve PF-573228 (Catalog No.S2013) for in vivo study (oral administration)?

  • Answer:

    PF-573228 in 30% PEG400+0.5% Tween80+ 5% Propylene glycol at 30mg/ml is a suspension. If you will use the compound for oral gavage, this suspension is fine for it.

Related Antibodies

FAK Signaling Pathway Map

Related FAK Products

Tags: buy PF-573228 | PF-573228 supplier | purchase PF-573228 | PF-573228 cost | PF-573228 manufacturer | order PF-573228 | PF-573228 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID